These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Quantitative structure-reactivity and structure-toxicity relationships of reactivators of phosphylated acetylcholinesterase. Mager PP Pharmazie; 1981 Jun; 36(6):450-1. PubMed ID: 7279998 [No Abstract] [Full Text] [Related]
5. Structure-activity relationships in reactivators of organophosphorus-inhibited acetylcholinesterase. XI - Bisquaternary compounds of beta-(4-pyridyl)acraldoxime. Antonini I; Cristalli G; Franchetti P; Grifantini M; Martelli S Farmaco Sci; 1977 Dec; 32(12):905-8. PubMed ID: 563345 [TBL] [Abstract][Full Text] [Related]
6. Current understanding of the application of pyridinium oximes as cholinesterase reactivators in treatment of organophosphate poisoning. Jokanović M; Stojiljković MP Eur J Pharmacol; 2006 Dec; 553(1-3):10-7. PubMed ID: 17109842 [TBL] [Abstract][Full Text] [Related]
7. [Therapeutic effectiveness of atropine and dipyroxime]. Khaitov RKh; Baĭmuradov TB; Kadyrov US Veterinariia; 1972 Nov; 11():86-7. PubMed ID: 4677483 [No Abstract] [Full Text] [Related]
8. Quantitative structure-activity relationships of reactivators of phosphylated acetylcholinesterase. Part 2. Mager PP; Das Gupta S Pharmazie; 1982 Aug; 37(8):607-8. PubMed ID: 7146070 [No Abstract] [Full Text] [Related]
9. In vitro studies on the reactivation by oximes of phosphylated acetylcholinesterase--I. On the reactions of P2S with various organophosphates and the properties of the resultant phosphylated oximes. Harvey B; Scott RP; Sellers DJ; Watts P Biochem Pharmacol; 1986 Mar; 35(5):737-44. PubMed ID: 3954783 [TBL] [Abstract][Full Text] [Related]
10. [The action of cholinesterase reactivators on the body not related to the recovery of the activity of phosphorylated acetylcholinesterase]. Shorokhov IuA; Zatsepin EP; Androsov NS Eksp Klin Farmakol; 1993; 56(4):62-6. PubMed ID: 8106061 [No Abstract] [Full Text] [Related]
11. Testing of antidotes for organophosphorus compounds: experimental procedures and clinical reality. Eyer P; Szinicz L; Thiermann H; Worek F; Zilker T Toxicology; 2007 Apr; 233(1-3):108-19. PubMed ID: 17010492 [TBL] [Abstract][Full Text] [Related]
12. Design and structure-activity relationships of antidotes to organophosphorus anticholinesterase agents. Gray AP Drug Metab Rev; 1984; 15(3):557-89. PubMed ID: 6386410 [No Abstract] [Full Text] [Related]
13. Anomalies in theories and therapy of intoxication by potent organophosphorus anticholinesterase compounds. Ellin RI Gen Pharmacol; 1982; 13(6):457-66. PubMed ID: 6759293 [No Abstract] [Full Text] [Related]
14. Oxime use after deliberate release. Johnston A; Rice P Crit Care Med; 2006 Dec; 34(12):3064-5; author reply 3065. PubMed ID: 17130717 [No Abstract] [Full Text] [Related]
15. [Use of oximes in the therapy of acute intoxication by organophosphorus compounds]. Raszewski G; Filip R Przegl Lek; 2004; 61(3):181-4. PubMed ID: 15518329 [TBL] [Abstract][Full Text] [Related]
16. [Comparison of the therapeutic effectiveness of selected cholinesterase reactivators with atropine in acute fosdrine poisoning in mice]. Kassa J; Bajgar J Ceska Slov Farm; 1996 Feb; 45(1):31-4. PubMed ID: 8620316 [TBL] [Abstract][Full Text] [Related]
17. [Progress in the treatment of acute organophosphate poisoning]. Zhang J; Zhao J Zhonghua Yu Fang Yi Xue Za Zhi; 1999 Jul; 33(4):248-9. PubMed ID: 15384239 [No Abstract] [Full Text] [Related]